The highly advanced non-invasive medical device that effectively resolves challenging face and body aesthetic needs, such as non-surgical cellulite reduction and wrinkle reduction*. Treatments are comfortable with no downtime using RF technology that is safe for all skin types. Venus Legacy™ is powered by proprietary (MP)2 technology (a combination of Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields) and features cutting-edge VariPulse™ technology.
Advanced technology and unique applicator design
Venus Legacy™ features four applicators: OctiPolar™ and 4D Body for larger areas, and DiamondPolar™ and 4D Face for smaller areas. All four applicators are powered by proprietary (MP)2 technology with the synergistic combination of Multi-Polar Radio Frequency (RF) and Pulsed Electro Magnetic Fields (PEMF). The OctiPolar™ and DiamondPolar™ applicators are indicated for wrinkle reduction treatments*, which leads to tightening of the skin. The 4D Body applicator is equipped with novel VariPulse™ technology, which makes it highly effective for cellulite reduction*.
|MULTI-POLAR RADIO FREQUENCY||PULSED ELECTRO MAGNETIC FIELDS||(MP)2 TECHNOLOGY|
Venus Legacy™ includes various features that enable a higher return on ownership, such as affordable pricing, cutting-edge technology for all skin types, and no disposables. Venus Concept's industry-unique business model is designed to even further increase the success of your business.
INDICATIONS FOR USE:
*Venus Legacy™ is cleared by the FDA for the non-invasive treatment of moderate to severe facial wrinkles and rhytides in females with Fitzpatrick skin types I-IV with the OctiPolar™ and DiamondPolar™ applicators, and temporary reduction in the appearance of cellulite with the 4D Body (LB2) and 4D Face (LF2) applicators.
1. Callaghan, M. J., Chang, E. I., Seiser, N., Aarabi, S., Ghali, S., Kinnucan, E. R., . . . Gurtner, G. C. (2008). Pulsed Electromagnetic Fields Accelerate Normal and Diabetic Wound Healing by Increasing Endogenous FGF-2 Release. Plastic and Reconstructive Surgery, 121(1), 130-141. doi:10.1097/01.prs.0000293761.27219.84